Publication | Open Access

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

OncologyMedicineVersus CarboplatinImmune Checkpoint InhibitorHigh-dose ChemotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer ResearchHigh-risk Neuroblastoma